버킷 림프종 치료제 시장 : 약물 계열별, 치료 단계별, 환자층별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Burkitt Lymphoma Therapeutics Market size was valued at US$ 1,287.1 Million in 2025, expanding at a CAGR of 8.1% from 2026 to 2033.

Burkitt Lymphoma Therapeutics are defined as a complete set of treatment approaches, supportive therapies, and interventions utilized in the treatment of this rare and extremely aggressive type of non-Hodgkin lymphoma. In general, the optimal treatment option for Burkitt lymphoma is aggressive chemotherapy that consists of a combination of intensive polychemotherapy protocols, such as R-COPADM, R-hyper-CVAD, and R-EPOCH with the monoclonal antibody rituximab, CNS sanctuary therapy, and tumor lysis syndrome prophylaxis.

Additionally, intensive treatment strategies are used based on the risk-adaptive approach taking into account the manner of presentation, tumor size, and patient's characteristics in order to achieve the best results in the course of treatment that will reduce the treatment-associated risks of mortality and morbidity. As a result, Burkitt lymphoma therapeutics are mostly focused on the curative treatment of the disease and involve a timely and comprehensive approach due to the high response rates to treatment.

Burkitt Lymphoma Therapeutics Market- Market Dynamics

Advancements in Precision Medicine To Fuel Market Growth

Advancements in precision medicine are driving increased demand for targeted therapy for Burkitt lymphoma since they assist health specialists in selecting the most efficient ways of treatment and making their therapy personalized. For example, in March 2025, the government of Australia made an announcement about the investment into the development of precision medicine programs totaling up to $143.4 million.

Among them, there was an allocation of $112.6 million, which would cover the cost of accessing the precision medicine program for over 2,000 children, and the program extension would provide access to the program of 300 more people per year so that eventually, it would provide access to around 1,300 children and youth each year. Another investment worth $30.8 million would help to extend the PrOSPeCT cancer genomics program that would allow matching therapies for more than two-thirds of 5,000 patients. These investments are expected to accelerate personalized treatment adoption and strengthen Burkitt lymphoma therapy development.

Burkitt Lymphoma Therapeutics Market- Segmentation Analysis:

The Global Burkitt Lymphoma Therapeutics Market is segmented on the basis of Drug Class, Line of Therapy, Patient Population, and Region.

In the Burkitt lymphoma therapeutics market, monoclonal antibodies hold a significant share because of their specific mode of action, increased use of the antibody in combinational therapy, and the specificity of its mode of action when used to treat Burkitt lymphoma patients. In November 2025, Takeda Pharmaceuticals registered positive results as far as the Phase 1b clinical trial of mezagitamab (TAK-079), which is an anti-CD38 monoclonal antibody characterized by sustained renal function in primary IgA nephropathy. Thus, specific antibodies are bringing advances in Burkitt lymphoma treatments.

In the patient population, adults hold a significant share in the Burkitt Lymphoma Therapeutics market because of the prevalence of Burkitt lymphoma among adults and also with the usage of therapies like chemotherapy, immunotherapy, and targeted therapy. In July 2026, AbbVie entered into an agreement with Genmab for evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of epcoritamab in relapsed/refractory aggressive mature B-cell neoplasms in pediatric/young adult patients (Burkitt lymphoma/leukemia) in a Phase 1b trial. The studies are currently underway and will continue until 2027. These developments support the continued therapeutic innovation for Burkitt lymphoma across adult and younger patient populations.

Burkitt Lymphoma Therapeutics Market- Geographical Insights

North America holds a prominent position in the Burkitt Lymphoma Therapeutics market because of various reasons, such as the availability of advanced healthcare services, the launching of innovative products, increasing investments in R&D activities, and rising consumer awareness. For instance, in January 2026, according to the American Heart Association, cardiovascular disease accounted for more than a quarter of all deaths in the U.S. The report reveals that 22% of all Americans die of heart disease, while 5.3% of American people die of stroke. 915,973 deaths from cardiovascular disease occurred in the U.S.

In addition, it was reported that 125.9 million (47.3%) adults in the U.S. have high blood pressure. It was also mentioned in the report that 29.5 million adults in the U.S. suffer from diabetes, and the number of obese or severely obese adults in the U.S. is 50%. Therefore, due to the increasing prevalence of diseases and awareness regarding them, it is anticipated that North America will boost the market growth with higher healthcare spending and disease management programs.

Burkitt Lymphoma Therapeutics Market- Competitive Landscape:

The top players involved in the Burkitt Lymphoma Therapeutics market through the use of different strategies such as targeted therapies, collaborations, and expanding the range of treatment therapies. The names of these players include Roche, Novartis, Bristol Myers Squibb, Abbvie Inc., and Gilead Sciences. In May 2026, Incyte Corporation collaborated with Edison Scientific using the Kosmos AI platform for target discovery, translational biology, and therapeutic research in oncology and other therapeutic areas. Such developments are contributing to the development of the targeted therapy segment in the field of Burkitt lymphoma therapeutics.

Recent Developments:

In May 2026, Kyowa Kirin stated its plans to open a new integrated research base in Japan so as to increase the capacities for drug discovery, translational research, and CMC (chemistry, manufacturing, and controls), as well as to encourage the interaction between all activities concerning the research and development of the company.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BURKITT LYMPHOMA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• AbbVie Inc.
• Bayer AG
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson
• Eli Lilly and Company
• Incyte Corporation
• Kyowa Kirin Co., Ltd.
• Seagen Inc.
• Karyopharm Therapeutics Inc.
• TG Therapeutics, Inc.
• Verastem Oncology
• Spectrum Pharmaceuticals, Inc.
• BeiGene Ltd.
• ADC Therapeutics SA
• Servier
• Others

GLOBAL BURKITT LYMPHOM MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033

• Monoclonal Antibodies
• Chemotherapy Agents
• Proteasome Inhibitors
• Checkpoint Inhibitors

GLOBAL BURKITT LYMPHOMA THERAPEUTICS MARKET, BY LINE OF THERAPY- MARKET ANALYSIS, 2020 - 2033

• First-Line Therapy
• Second-Line Therapy and Beyond

GLOBAL BURKITT LYMPHOMA THERAPEUTICS MARKET, BY PATIENT POPULATION- MARKET ANALYSIS, 2020 - 2033

• Adults
• Pediatric

GLOBAL BURKITT LYMPHOMA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Denmark
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Taiwan
• Vietnam
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Iran
• Qatar
• Rest of MEA

Table of Contents

1. Burkitt Lymphoma Therapeutics Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
• 2.2. Competitive Insights

3. Burkitt Lymphoma Therapeutics Key Market Trends

• 3.1. Burkitt Lymphoma Therapeutics Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Burkitt Lymphoma Therapeutics Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Burkitt Lymphoma Therapeutics Market Opportunities
• 3.4. Burkitt Lymphoma Therapeutics Market Future Trends

4. Burkitt Lymphoma Therapeutics Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Burkitt Lymphoma Therapeutics Market : Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Burkitt Lymphoma Therapeutics Market Landscape

• 6.1. Burkitt Lymphoma Therapeutics Market Share Analysis, 2025
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Burkitt Lymphoma Therapeutics Market - By Drug Class

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
  • 7.1.2. Monoclonal Antibodies
  • 7.1.3. Chemotherapy Agents
  • 7.1.4. Proteasome Inhibitors
  • 7.1.5. Checkpoint Inhibitors

8. Burkitt Lymphoma Therapeutics Market - By Line of Therapy

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Line of Therapy, 2025 & 2033 (%)
  • 8.1.2. First-Line Therapy
  • 8.1.3. Second-Line Therapy and Beyond

9. Therapeutics Market - By Patient Population

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Patient Population, 2025 & 2033 (%)
  • 9.1.2. Adults
  • 9.1.3. Pediatric

10. Burkitt Lymphoma Therapeutics Market - By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Burkitt Lymphoma Therapeutics Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Burkitt Lymphoma Therapeutics Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.8. UK
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.8.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.8.4. UK Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.8.5. UK Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.9. France
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.9.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.9.4. France Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.9.5. France Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.10. Italy
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.10.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.10.4. Italy Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.10.5. Italy Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.11. Spain
    • 10.3.11.1. Overview
    • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.11.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.11.4. Spain Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.11.5. Spain Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.12. The Netherlands
    • 10.3.12.1. Overview
    • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.12.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.12.4. The Netherlands Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.12.5. The Netherlands Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Overview
    • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.13.5. Sweden Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.14. Russia
    • 10.3.14.1. Overview
    • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.14.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.14.4. Russia Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.14.5. Russia Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.15. Poland
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.15.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.15.4. Poland Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.15.5. Poland Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.16. Denmark
    • 10.3.16.1. Overview
    • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.16.3. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.16.4. Denmark Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.16.5. Denmark Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.3.17. Rest of Europe
    • 10.3.17.1. Overview
    • 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.3.17.4. Rest of the Europe Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.3.17.5. Rest of the Europe Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Burkitt Lymphoma Therapeutics Key Manufacturers in Asia Pacific
  • 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 10.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  • 10.4.5. APAC Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
  • 10.4.6. APAC Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.7. China
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.7.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.7.4. China Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.7.5. China Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.8. India
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.8.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.8.4. India Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.8.5. India Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.12. Indonesia
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.12.4. Indonesia Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.12.5. Indonesia Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.13. Thailand
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.13.4. Thailand Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.13.5. Thailand Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.15. Taiwan
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.15.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.15.4. Taiwan Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.15.5. Taiwan Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.16. Vietnam
    • 10.4.16.1. Overview
    • 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.16.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.16.4. Vietnam Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.16.5. Vietnam Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.4.17. Rest of APAC
    • 10.4.17.1. Overview
    • 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.4.17.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.4.17.4. Rest of APAC Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.4.17.5. Rest of APAC Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
• 10.5. Latin America (LATAM)
  • 10.5.1. Overview
  • 10.5.2. Burkitt Lymphoma Therapeutics Key Manufacturers in Latin America
  • 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 10.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  • 10.5.5. LATAM Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
  • 10.5.6. LATAM Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
• 10.6. Middle East and Africa (MEA)
  • 10.6.1. Overview
  • 10.6.2. Burkitt Lymphoma Therapeutics Key Manufacturers in Middle East and Africa
  • 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 10.6.4. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  • 10.6.5. MEA Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
  • 10.6.6. MEA Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.6.8. UAE
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.6.8.3. UAE Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.6.8.4. UAE Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.6.8.5. UAE Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.6.13. Iran
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.6.13.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.6.13.4. Iran Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.6.13.5. Iran Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.6.14. Qatar
    • 10.6.14.1. Overview
    • 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.6.14.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.6.14.4. Qatar Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.6.14.5. Qatar Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)
  • 10.6.15. Rest of MEA
    • 10.6.15.1. Overview
    • 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 10.6.15.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
    • 10.6.15.4. Rest of MEA Market Size and Forecast, By Line of Therapy, 2020 - 2033 (US$ Million)
    • 10.6.15.5. Rest of MEA Market Size and Forecast, By Patient Population, 2020 - 2033 (US$ Million)

11. Key Vendor Analysis- Burkitt Lymphoma Therapeutics Industry

• 11.1. Competitive Benchmarking
  • 11.1.1. Competitive Dashboard
  • 11.1.2. Competitive Positioning
• 11.2. Company Profiles
  • 11.2.1. AbbVie Inc.
  • 11.2.2. Bayer AG
  • 11.2.3. Sanofi S.A.
  • 11.2.4. Takeda Pharmaceutical Company Limited
  • 11.2.5. Johnson & Johnson
  • 11.2.6. Eli Lilly and Company
  • 11.2.7. Incyte Corporation
  • 11.2.8. Kyowa Kirin Co., Ltd.
  • 11.2.9. Seagen Inc.
  • 11.2.10. Karyopharm Therapeutics Inc.
  • 11.2.11. TG Therapeutics, Inc.
  • 11.2.12. Verastem Oncology
  • 11.2.13. Spectrum Pharmaceuticals, Inc.
  • 11.2.14. BeiGene Ltd.
  • 11.2.15. ADC Therapeutics SA
  • 11.2.16. Servier
  • 11.2.17. Others

12. 360 Degree AnalystView

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us